Loading
RECIP judges response on PSMA PET scans by the change in the total volume of PSMA-positive tumour and the appearance of new spots, and was built in men treated with lutetium-PSMA.
Gafita and colleagues (Journal of Nuclear Medicine 2022) studied 124 men with metastatic castration-resistant prostate cancer treated with lutetium-177 PSMA who had PSMA PET at baseline and 12 weeks. RECIP 1.0 defines complete response as no PSMA uptake; partial response as a fall of 30% or more in PSMA-positive tumour volume without new lesions; progression as a rise of 20% or more with new lesions; and stable disease as anything else. Median survival was 8.3 months with RECIP progression against 13.1 months with stable disease. A composite with PSA (PSA + RECIP) is proposed as a trial endpoint.
Showing the technology this term belongs to: PSMA PET.
Shares PSMA-RADS (PSMA PET reporting system), PCWG3 (Prostate Cancer Clinical Trials Working Group 3), Prostate cancer.
Shares Lutetium-177 radioligand therapy, PSMA PET, Prostate cancer.
Shares PCWG3 (Prostate Cancer Clinical Trials Working Group 3), RECIST.
Shares RECIST, Prostate cancer.
Shares PSMA PET, Prostate cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/